European Pharmaceutical Review

SEPTEMBER 12, 2023

Initial data from the CPHI Annual Report 2023, which provides insight from 250 global pharmaceutical companies, reveals that AI (artificial intelligence) is expected to transform every area of the industry, from drug discovery through to drug development , within the next 24-months.

FDA 95

FDA Pharmaceutical Companies Pharmaceutical Companies 95

STAT

AUGUST 22, 2023

German drugmaker Boehringer Ingelheim is the latest pharmaceutical company to sue the federal government over a law that would allow Medicare to negotiate certain drug prices, Reuters reports. Continue to STAT+ to read the full story…

Vaccines 87

Vaccines FDA Pharmaceutical Companies Pharmaceutical Companies 87

PharmaShots

FEBRUARY 21, 2023

With the growing influence of radiopharmaceutical companies in oncology, the companies hold a firm grasp on the market. With the expanding acceptance among HCPs, patients, and researchers, radiopharmaceutical companies are estimated to touch the $7.5B threshold by 2026.

FDA 56

FDA Dosage Pharmaceutical Companies Pharmaceutical Companies 56

Pharmaceutical Technology

JANUARY 10, 2023

There are multiple drugs in the pipeline, predominantly me-too and biosimilar therapies, with a significant number developed in the emerging markets of India and China by domestic pharmaceutical companies for their own rapidly growing markets.

Labelling 52

Labelling Compounding Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Technology

APRIL 28, 2023

The company undertook several initiatives recently to expand its business through new partnerships, expansion of existing relationships, and investment in manufacturing capacity. Key among them has been the extension of Syngene’s research collaboration with leading biotech company Amgen Inc. until 2026.

FDA 52

FDA Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

JUNE 29, 2022

COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026. Sarah Rickwood has 30 years’ experience as a consultant to the pharmaceutical industry. The scope of the problem.

HIV Treatment and Prevention Agents 58

HIV Treatment and Prevention Agents Vaccines Pharmaceutical Companies Pharmaceutical Companies 58